These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2643665)

  • 21. Binding to complement factors and activation of the alternative pathway by Acanthamoeba.
    Pumidonming W; Walochnik J; Dauber E; Petry F
    Immunobiology; 2011; 216(1-2):225-33. PubMed ID: 20627448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of complement activation at the C3-level by serum resistant leptospires.
    Meri T; Murgia R; Stefanel P; Meri S; Cinco M
    Microb Pathog; 2005 Oct; 39(4):139-47. PubMed ID: 16169184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
    Mold C; Nemerow GR; Bradt BM; Cooper NR
    J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A molecular mechanism of complement resistance of human melanoma cells.
    Panneerselvam M; Welt S; Old LJ; Vogel CW
    J Immunol; 1986 Apr; 136(7):2534-41. PubMed ID: 3081645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding and release of C3 from Leishmania donovani promastigotes during incubation in normal human serum.
    Puentes SM; Dwyer DM; Bates PA; Joiner KA
    J Immunol; 1989 Dec; 143(11):3743-9. PubMed ID: 2584716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum resistance and biofilm formation in clinical isolates of Acinetobacter baumannii.
    King LB; Swiatlo E; Swiatlo A; McDaniel LS
    FEMS Immunol Med Microbiol; 2009 Apr; 55(3):414-21. PubMed ID: 19220466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement lysis of U937, a nucleated mammalian cell line in the absence of C9: effect of C9 on C5b-8 mediated cell lysis.
    Morgan BP; Imagawa DK; Dankert JR; Ramm LE
    J Immunol; 1986 May; 136(9):3402-6. PubMed ID: 3514758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of the alternative complement pathway by Leishmania promastigotes: parasite lysis and attachment to macrophages.
    Mosser DM; Edelson PJ
    J Immunol; 1984 Mar; 132(3):1501-5. PubMed ID: 6363545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The third component of complement (C3) bound to tumor target cells enhances their sensitivity to killing by activated macrophages.
    Bara S; Lint TF
    J Immunol; 1987 Feb; 138(4):1303-9. PubMed ID: 3100634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complement resistance in Borrelia burgdorferi strain 297: outer membrane proteins prevent MAC formation at lysis susceptible sites.
    Patarakul K; Cole MF; Hughes CA
    Microb Pathog; 1999 Jul; 27(1):25-41. PubMed ID: 10371707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Behaviour of Toxoplasma gondii RH Ankara strain tachyzoites during continuous production in various cell lines.
    Döskaya M; Degirmenci A; Ciçek C; Ak M; Korkmaz M; Gürüz Y; Uner A
    Parasitology; 2006 Mar; 132(Pt 3):315-9. PubMed ID: 16318650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps.
    Ollert MW; Kadlec JV; David K; Petrella EC; Bredehorst R; Vogel CW
    J Immunol; 1994 Sep; 153(5):2213-21. PubMed ID: 8051421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leishmania (Viannia) braziliensis: interaction of mannose-binding lectin with surface glycoconjugates and complement activation. An antibody-independent defence mechanism.
    Ambrosio AR; De Messias-Reason IJ
    Parasite Immunol; 2005 Sep; 27(9):333-40. PubMed ID: 16149991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The elevated natural killer sensitivity of targets carrying surface-attached C3 fragments require the availability of the iC3b receptor (CR3) on the effectors.
    Ramos OF; Kai C; Yefenof E; Klein E
    J Immunol; 1988 Feb; 140(4):1239-43. PubMed ID: 2963864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of enhanced complement-dependent cytotoxicity of papain-treated lymphocytes: evidence for increased stability of classical pathway C3 convertase.
    Lublin DM; Grumet FC
    J Immunol; 1982 Feb; 128(2):866-70. PubMed ID: 6915075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenesis of Campylobacter fetus infections. Failure of encapsulated Campylobacter fetus to bind C3b explains serum and phagocytosis resistance.
    Blaser MJ; Smith PF; Repine JE; Joiner KA
    J Clin Invest; 1988 May; 81(5):1434-44. PubMed ID: 3366901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
    Kievits F; Kijlstra A
    Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing.
    Tesh VL; Duncan RL; Morrison DC
    J Immunol; 1986 Aug; 137(4):1329-35. PubMed ID: 3525676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sub-minimal inhibitory concentrations of cefmetazole enhance serum bactericidal activity in vitro by amplifying poly-C9 deposition.
    Schweinle JE; Nishiyasu M
    J Clin Invest; 1992 Apr; 89(4):1198-207. PubMed ID: 1556181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.